Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Michael W. Schuster, MD, Mikkael A. Sekeres, MD MS, Erick Gamelin, MD PhD, Erik Rasmussen, MS, Gloria Juan, PhD, Abraham Anderson, PhD, Vincent Chow, PhD, Greg Friberg, MD, Florian D. Vogl, MD PhD, Hagop Kantarjian, MD

Blood (2015) 126 (23): 4929.

https://doi.org/10.1182/blood.V126.23.4929.4929

Published: 2015

Journal Articles

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Laurie Jones-Jackson, MD, Elias J. Anaissie, MD, Terri L. Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD.

Blood (2005) 106 (11): 5079.

https://doi.org/10.1182/blood.V106.11.5079.5079

Published: 2005

Journal Articles

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Federica Cavallo, MD, Laurie Jones-Jackson, MD, Elias Anaissie, MD, Terri Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 3493.

https://doi.org/10.1182/blood.V106.11.3493.3493

Published: 2005

Journal Articles

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Ichiro Hanamura, MD, Peter Stewart, PhD, Frederica Cavallo, MD, Bart Burington, MS, Erik Rasmussen, MS, John Crowley, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, MS, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2005) 106 (11): 1553.

https://doi.org/10.1182/blood.V106.11.1553.1553

Published: 2005

Journal Articles

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Michele Cottler-Fox, MD, David Holley, BA, Linda Whigham, HNC, Julie Stover, BA, Erik Rasmussen, MS, Maurizio Zangari, MD, Guido Tricot, MD, PhD, Barthel Barlogie, MD, PhD

Blood (2004) 104 (11): 2884.

https://doi.org/10.1182/blood.V104.11.2884.2884

Published: 2004

NARROW

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only